-
Company Insights
Innovation and Patenting activity of Oncopeptides AB Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Oncopeptides AB Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be delivered...
-
Product Insights
Plasma Cell Neoplasm – Drugs In Development, 2023
Global Markets Direct’s, ‘Plasma Cell Neoplasm - Drugs In Development, 2023’, provides an overview of the Plasma Cell Neoplasm pipeline landscape. The report provides comprehensive information on the therapeutics under development for Plasma Cell Neoplasm, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Company Profile
NewOncopeptides AB – Company Profile
Oncopeptides AB (Oncopeptides) is a biotechnology company that focuses on research, development and commercialization of therapies for hematological diseases. Its lead product includes Melflufen, a peptide drug conjugate, which is used to treat hematological cancer and relapsed and refractory multiple myeloma. Oncopeptides utilizes its proprietary Peptide Drug Candidate platform PDC to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells and small polypeptide based killer engagers (SPiKE) for the treatment of multiple myeloma. The company operates in...
Add to Basket -
Product Insights
Acute Myelocytic Leukemia (AML) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
AML Pipeline Products Market Report Overview Acute myelocytic leukemia (AML), also known as acute myelogenous leukemia is a type of cancer that affects the blood and the bone marrow. Immature white blood cells accumulate in the bone marrow thus blocking the production of normal blood cells. These cells further enter the bloodstream and spread to the other parts of the body. Symptoms of AML include fatigue, fever, bleeding, breathing problems, and weight loss. The predisposing factors involved are exposed to...
-
Product Insights
Multiple Myeloma (Kahler Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Multiple Myeloma Pipeline Products Market Report Overview Multiple myeloma is a type of cancer that is caused by malignant plasma cells that proliferate in the bone marrow and produce abnormally high amounts of a special protein. The exact cause of multiple myeloma is not clear. It mainly affects older adults. Symptoms include anemia, bleeding, nerve damage, skin lesions, bone tenderness or pain, and kidney failure. Treatment includes chemotherapy, radiation, immunosuppression, and surgery. The Multiple Myeloma Drugs in Development market research...
-
Product Insights
Net Present Value Model: Pepaxto
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Pepaxto Drug Details Melphalan flufenamide hydrochloride...
-
Product Insights
Non-Hodgkin Lymphoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Non-Hodgkin lymphoma (also known as non-Hodgkin’s lymphoma, NHL, or sometimes just lymphoma) is a cancer that starts in cells called lymphocytes, which are part of the body’s immune system. Symptoms may include night sweats, fever and chills that come and go, itching, putting pressure on the windpipe (trachea) or other airways, abdominal pain or swelling, leading to loss of appetite, constipation, nausea, and vomiting and headache, concentration problems, personality changes, or seizures if cancer affects the brain. Treatment includes surgery,...
-
Sector Analysis
Global Hematological Cancer (Blood Cancer) Therapy Market to 2027 – Comprehensive Overview of Marketed and Pipeline Products, Opportunities, Challenges, Market Size and Key Players
The market value for therapies used in the treatment of hematological cancers has increased substantially in the past 10 years. The total sales for marketed therapeutics for hematological cancers were valued at $58 billion in 2020. The total sales include the sales of branded and biosimilar marketed agents, but not generics. The hematological cancer therapy market is diverse and highly genericized. There are 2,406 marketed molecules for the treatment of hematological cancers available globally. The majority of these are generic...
-
Sector Analysis
Multiple Myeloma – Global Drug Forecast and Market Analysis to 2027
Multiple myeloma (MM) is a cancer of abnormal plasma cells, a type of white blood cell that is normally responsible for producing antibodies in the bone marrow. It is the second most common hematological malignancy in the US, and constitutes less than 1% of all cancer types. Multiple myeloma is not considered curable, but is treatable, with many therapies being generic steroids, and chemotherapies. Significant improvements in treatment outcome were achieved with the introduction of the immunomodulatory (IMiD) agents Thalomid...